Remove 2003 Remove Biosimilars Remove Diabetes
article thumbnail

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots

Through the inclusion of Pharmacia’s products along with a strong performance, Pfizer’s pharmaceutical and animal health revenue was boosted by 40% and 43% respectively In the year 2003, Johnson & Johnson generated a revenue of $41.9B which depicted a growth of 15.3% as compared to the previous year. from last year.

article thumbnail

A history of Johnson & Johnson

pharmaphorum

During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. Beginning in 2003, J&J became involved in a series of litigations with Boston Scientific involving patents covering heart stent medical devices. Acquisitions post-Janssen. Between 1976 and 1989, James E.

Vaccines 126